Document and Entity Information |
Mar. 03, 2022 |
|---|---|
| Cover [Abstract] | |
| Amendment Flag | true |
| Entity Central Index Key | 0001750149 |
| Document Type | 8-K/A |
| Document Period End Date | Mar. 03, 2022 |
| Entity Registrant Name | INHIBIKASE THERAPEUTICS, INC. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-39676 |
| Entity Tax Identification Number | 26-3407249 |
| Entity Address, Address Line One | 3350 Riverwood Parkway SE |
| Entity Address, Address Line Two | Suite 1900 |
| Entity Address, City or Town | Atlanta |
| Entity Address, State or Province | GA |
| Entity Address, Postal Zip Code | 30339 |
| City Area Code | (678) |
| Local Phone Number | 392-3419 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, $0.001 par value |
| Trading Symbol | IKT |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | false |
| Amendment Description | On March 8, 2022, Inhibikase Therapeutics, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”) regarding certain amendments to the employment agreements of Milton H. Werner Ph.D., its President and Chief Executive Officer, and of Joseph Frattaroli, its Chief Financial Officer. The Company is filing this amended report to correct an error regarding the effective date of the increase to the base salary of each of Dr. Werner and Mr. Frattaroli. The full text of the Original Form 8-K is set forth below as previously filed, except with the corrected dates as described above. |